



euroPLX Business Developer

Vol. 15 # 12 | December | 2019

Sluggish Year-End Mergers and Acquisitions Activities - Season's Greetings!

* Acquisition: **Alkermes, Inc.** has completed its previously announced acquisition of **Rodin Therapeutics, Inc.**, a privately held biopharmaceutical company. At the closing of the transaction, Alkermes made an upfront cash payment of \$100 million (subject to customary adjustments) to Rodin's former security holders. Rodin's former security holders are eligible to receive future payments of up to \$850 million upon achievement by Rodin's development candidates. 25 Nov 2019 (www.alkermes.com)

* Acquisition: **Amgen** completed the acquisition of worldwide rights to **Otezla®** (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from **Celgene Corporation** in connection with its previously announced merger with Bristol-Myers Squibb Company, which was completed on Nov. 20. 21 Nov 2019 (www.amgen.com)

* **Astellas Pharma Inc.** and **Audentes Therapeutics, Inc.** have entered into a definitive agreement for Astellas to acquire Audentes for US\$60.00 per share in cash, representing an equity value of about US\$3 billion. 3 Dec 2019 (www.astellas.com)

* Acquisition: **Avanos Medical, Inc.** completed the acquisition of **Endoclear LLC**, a developer and marketer of airway management devices and accessories, including its Liberator® System and Restore2™ proprietary products, for an initial purchase price of \$3.5 million. 5 Nov 2019 (avanos.com)

* Acquisition: **Bristol-Myers Squibb Company** has completed its acquisition of **Celgene Corporation** following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. 20 Nov 2019 (www.bms.com)

* Acquisition: **Cambrex Corporation**, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients has now completed its previously announced sale to an affiliate of the **Permira** funds. 4 Dec 2019 (www.cambrex.com)

* Distribution: **CASI Pharmaceuticals, Inc.**, a U.S. biopharmaceutical company announced an exclusive distribution agreement with **Pharmathen Global BV** for the development and distribution of octreotide long acting injectable microspheres in China. 7 Nov 2019

(www.casipharmaceuticals.com/)

* Acquisition: **COI Pharmaceuticals** announced the acquisition of **Calporta Therapeutics, Inc.** by **Merck**, known as **MSD** outside the United States and Canada. Calporta develops selective small molecule agonists to TRPML1 which is believed to play a role in lysosomal function. Merck acquired Calporta for total potential consideration of up to \$576 mn, including an upfront payment and contingent milestone payments. 13 Nov 2019 (www.coipharma.com)

* **Exact Sciences Corp.** has completed its previously announced combination with **Genomic Health, Inc.** The transaction is valued at \$2.8 billion. Together, Exact Sciences and Genomic Health plan to create a leading global cancer diagnostics company. 8 Nov 2019 (www.exactsciences.com)

* Acquisition: **Novartis AG's** indirect wholly-owned subsidiary, **Medusa Merger Corporation**, a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding shares of common stock, par value USD 0.001 per share, of **The Medicines Company** for a price of USD 85.00 per share. 5 Dec 2019 (www.novartis.com)

* Acquisition: **Sandoz** has entered into a binding agreement for the planned acquisition of the Japanese business of **Aspen Global Incorporated**, a wholly owned subsidiary of **Aspen Pharmacare Holdings Limited**. The planned acquisition consists of shares in **Aspen Japan K.K.** and associated assets held by AGI. Pursuant to the agreed terms of the transaction, on closing Sandoz will pay an initial sum of EUR 300 million. Sandoz has also agreed, upon certain conditions being fulfilled after closing, to pay certain deferred consideration to AGI. It is currently anticipated that the amount of deferred consideration to be paid will not exceed EUR 100 million. 11 Nov 2019 (www.sandoz.com)

BD People on the Move

* Medochemie Ltd.: **Andreas Loizou** who previously served as Licensing Manager and Finance Manager (Overseas), and a euroPLX Gold Bell Club Member, has been appointed as Group Business Development Director. Andreas will continue to hold the position of Managing Director of the Medochemie subsidiary Dutch manufacturing company F.A.L. BV. (Pers Comm 21 Nov 2019)

We wish you a happy 2020!